NervGen Pharma (NGEN) Stock Price, News & Analysis

Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies that promote repair and recovery in the nervous system. The company’s research is based on the potential to enhance the body’s natural ability to regenerate damaged nerve tissue and restore lost neurological function.

NervGen’s lead product candidate, NVG-291, is an investigational peptide designed to stimulate nervous-system repair after injury. The company has been evaluating NVG-291 in clinical development for conditions including spinal cord injury, with additional potential applications in neurological disorders such as multiple sclerosis and peripheral nerve damage.

Headquartered in Vancouver, British Columbia, NervGen serves the global biotechnology and healthcare markets through its research and clinical-development programs. The company’s leadership includes President and Chief Executive Officer Mike Kelly. NervGen Pharma trades on the Nasdaq Capital Market under the symbol NGEN and on the Toronto Stock Exchange Venture Exchange under the same symbol.

Key Stats

• Today's Range: $1.71 to $1.79
• 50-Day Range: $1.66 to $2.34
• 52-Week Range: $1.58 to $6.30
• Volume: 220,502 shs
• Average Volume: 466,214 shs
• Market Capitalization: $139.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

NervGen Pharma Stock Analysis - MarketRank™

NervGen Pharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 659th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NervGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NervGen Pharma has a consensus price target of $14.00, representing about 709.2% upside from its current price of $1.73.

Amount of Analyst Coverage

NervGen Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NervGen Pharma are expected to decrease in the coming year, from ($0.46) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NervGen Pharma is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NervGen Pharma is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NervGen Pharma has a P/B Ratio of 57.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.68% of the float of NervGen Pharma has been sold short.

Short Interest Ratio / Days to Cover

NervGen Pharma has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.

Change versus previous month

Short interest in NervGen Pharma has recently increased by 6.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NervGen Pharma does not currently pay a dividend.

Dividend Growth

NervGen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 1.82

News Sentiment

NervGen Pharma has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NervGen Pharma this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for NGEN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

6 people have added NervGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NervGen Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

NervGen Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NGEN
• CIK: 1751912
• Web: nervgen.com
• Phone: (604) 722-5361
• Fax: N/A
• Employees: 8
• Year Founded: 2017

Price Target and Rating

• Average Price Target for NervGen Pharma: $14.00
• High Price Target: $18.00
• Low Price Target: $10.00
• Potential Upside/Downside: +709.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,259.82%
• Return on Assets: -199.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 57.67

Miscellaneous

• Outstanding Shares: 80,630,000
• Free Float: N/A
• Market Cap: $139.49 million
• Optionable: N/A
• Beta: N/A